Although many traditional systemic drugs or biological agents are available for the treatment of psoriasis, there is an unmet medical need for this disease. Recently, Dr. Yiu ZZN from the University of Manchester in England introduced the new oral psoriasis therapy approved or still under development. The review, published in Am J Clin Dermatol, is summarized as follows:
is a phosphodiesterase (PDE) -4 inhibitor approved by the US Food and Drug Administration (US-FDA) and the European Medicines Agency (EMA) in 2014 for the treatment of psoriasis And Psoriatic Arthritis (PsA).
Two phase III randomized controlled trials (RCTs) showed that the efficacy of anastreptics (30 mg bid) for 16 weeks was significantly superior to placebo for psoriatic lesions including scalp and nail damage. A phase III RCT showed that the efficacy of apster (20 or 30 mg bid) for 16 weeks on PsA was significantly better than placebo.
The most common adverse events reported in Adler were diarrhea (17.8%), nausea (16.6%) and upper respiratory tract infection (8.4%), similar to placebo, with no significant laboratory abnormalities observed.
Compared with traditional non-biologic system therapies, Costster is expensive and can not be treated as a first-line treatment. The advantage of Aspotek is that it is effective for both psoriasis and PsA without increasing the risk of tuberculosis and without the need for laboratory monitoring. However, long-term observational studies should further establish the safety profile of this product.